SlideShare a Scribd company logo
1 of 11
Download to read offline
Regulatory affairs service
support
Rayna Kostova
Regulatory affairs and PV expert,
MPharm
Medicaldevices
&
medicovigilance
Pricing and
Reimbursement
Rayna Kostova, Regulatory affairs and Pharmacovigilance services 1
Registration of new
medicinal products in
EU countries: national
MRP, DCP, CP
preparation of documentation, negotiation
with local Authorities and submission in
Bulgaria (other EU countries)
2
Variation procedures
acc. to EU legislation
preparation of documentation, negotiation
with local Authorities and submission in
Bulgaria (other EU countries)
Product information changes, labelling
and leaflet variations (acc. to QRD
template requirements)
3
Medical devices
registration/notificati
ons acc. to EU
requirements
preparation of documentation, negotiation
with local Authorities and submission in
Bulgaria (other EU countries)
Product information: label, leaflet text
translations, proof-reading for BG
4
Biocidal products
registration acc. to
national and EU
requirements
preparation of documentation (technical
dossier), negotiation with local
Authorities and submission in Bulgaria
(other EU countries)
Product information: label, leaflet text
translations, proof-reading for BG
5
Food for special medical
purposes, food supplement and
cosmetic products
registration/notifications acc.
to EU requirements
preparation of documentation, negotiation
with local Authorities and submission in
Bulgaria (other EU countries)
Product information: label, leaflet text
translations, proof-reading for BG
6
Price registrations and
reimbursement procedures
preparation of documentation, negotiation with local Authorities
and submission in Bulgaria (other EU countries)
Market competitors prices research, long
term pricing strategy with internal and
external price referencing (17 Ref.
countries for BG)
Positive Drug list procedure for
reimbursement by the National Health
Insurance Fund and the hospital budget
7
Pharmacovigilance and
Medicovigilance
services
Literature screening for ADR
ADR reporting to local Authorities in BG
PSUR and RMP submission
Service as a Qualified person for PV
(QPPV) for the country
Collecting and reporting AE for Medical
devices
8
Product complaint
management
Receive, process, report signals of
complaints for drugs, medical devices,
biocides, enteral nutrition products and
cosmetics
Plan and propose corrective and
preventive actions (CAPA), submit FSN,
perform recalls and report to Authorities
Maintain complete database with complaint
signals and CAPA performed acc. to
internal and legal requirements 9
Quality management
system (QMS)
Create and maintain a system of
relevant SOP for RA, PV, GDP acc.
to company requirements and local
legislation
Support company during preparation
and conduction of internal/external
ISO audits
10
GOOD DISTRIBUTION PRACTICE
(GDP)
License as responsible pharmacist of
local warehouse for medicinal products in
Bulgaria
Experience as warehouse manager acc. to
local BG legislation requirements
Compliance with EU Legislation changes
support
11

More Related Content

What's hot

Priscription drug user free act......sn
Priscription drug user free act......snPriscription drug user free act......sn
Priscription drug user free act......snbdvfgbdhg
 
pharmaceutical policy - 2002
 pharmaceutical policy - 2002 pharmaceutical policy - 2002
pharmaceutical policy - 2002Suvarta Maru
 
The eu-clinical-trials-regulation-main-changes-and-challenges
The eu-clinical-trials-regulation-main-changes-and-challengesThe eu-clinical-trials-regulation-main-changes-and-challenges
The eu-clinical-trials-regulation-main-changes-and-challengesGeorgi Daskalov
 
overview of Japan pharmaceutical regulatory authority - PMDA
overview of Japan  pharmaceutical regulatory authority - PMDAoverview of Japan  pharmaceutical regulatory authority - PMDA
overview of Japan pharmaceutical regulatory authority - PMDANandhanan
 
Drug Price Control Order 2013
Drug Price Control Order 2013Drug Price Control Order 2013
Drug Price Control Order 2013Gaurav Andhansare
 
National Pharmaceutical Pricing Authority and DPCO 2013
National Pharmaceutical Pricing Authority and DPCO 2013National Pharmaceutical Pricing Authority and DPCO 2013
National Pharmaceutical Pricing Authority and DPCO 2013Ashish Chaudhari
 
Pharmaceutical Regulations in GCC countries
Pharmaceutical Regulations in GCC countriesPharmaceutical Regulations in GCC countries
Pharmaceutical Regulations in GCC countriesIman Ajami
 
Changing Regulatory Landscape of 2017
Changing Regulatory Landscape of 2017Changing Regulatory Landscape of 2017
Changing Regulatory Landscape of 2017aidentyler6
 
Registration requirments for cis countries
Registration requirments for cis countriesRegistration requirments for cis countries
Registration requirments for cis countriesJAYA PRAKASH VELUCHURI
 
Registration procedure of drugs in european union
Registration procedure of drugs in european unionRegistration procedure of drugs in european union
Registration procedure of drugs in european unionbdvfgbdhg
 
TGA presentation: Legislation and patient access schemes for medicinal cannabis
TGA presentation: Legislation and patient access schemes for medicinal cannabisTGA presentation: Legislation and patient access schemes for medicinal cannabis
TGA presentation: Legislation and patient access schemes for medicinal cannabisTGA Australia
 
US, EU & Japan GMP Requirements: Practical ICH Area Differences & Healthcare ...
US, EU & Japan GMP Requirements: Practical ICH Area Differences & Healthcare ...US, EU & Japan GMP Requirements: Practical ICH Area Differences & Healthcare ...
US, EU & Japan GMP Requirements: Practical ICH Area Differences & Healthcare ...AudioEducator
 
Centralize & decentralize regulatory framework of brazil and south africa
Centralize & decentralize regulatory framework of brazil and south africaCentralize & decentralize regulatory framework of brazil and south africa
Centralize & decentralize regulatory framework of brazil and south africaHarishankar Sahu
 

What's hot (20)

Priscription drug user free act......sn
Priscription drug user free act......snPriscription drug user free act......sn
Priscription drug user free act......sn
 
pharmaceutical policy - 2002
 pharmaceutical policy - 2002 pharmaceutical policy - 2002
pharmaceutical policy - 2002
 
The eu-clinical-trials-regulation-main-changes-and-challenges
The eu-clinical-trials-regulation-main-changes-and-challengesThe eu-clinical-trials-regulation-main-changes-and-challenges
The eu-clinical-trials-regulation-main-changes-and-challenges
 
overview of Japan pharmaceutical regulatory authority - PMDA
overview of Japan  pharmaceutical regulatory authority - PMDAoverview of Japan  pharmaceutical regulatory authority - PMDA
overview of Japan pharmaceutical regulatory authority - PMDA
 
Drug Price Control Order 2013
Drug Price Control Order 2013Drug Price Control Order 2013
Drug Price Control Order 2013
 
National Pharmaceutical Pricing Authority and DPCO 2013
National Pharmaceutical Pricing Authority and DPCO 2013National Pharmaceutical Pricing Authority and DPCO 2013
National Pharmaceutical Pricing Authority and DPCO 2013
 
Pharmaceutical Regulations in GCC countries
Pharmaceutical Regulations in GCC countriesPharmaceutical Regulations in GCC countries
Pharmaceutical Regulations in GCC countries
 
Changing Regulatory Landscape of 2017
Changing Regulatory Landscape of 2017Changing Regulatory Landscape of 2017
Changing Regulatory Landscape of 2017
 
Provisions for drug registration CFDA
Provisions for drug registration CFDAProvisions for drug registration CFDA
Provisions for drug registration CFDA
 
Registration requirments for cis countries
Registration requirments for cis countriesRegistration requirments for cis countries
Registration requirments for cis countries
 
Checklist of Requirements
Checklist of RequirementsChecklist of Requirements
Checklist of Requirements
 
Registration procedure of drugs in european union
Registration procedure of drugs in european unionRegistration procedure of drugs in european union
Registration procedure of drugs in european union
 
TGA presentation: Legislation and patient access schemes for medicinal cannabis
TGA presentation: Legislation and patient access schemes for medicinal cannabisTGA presentation: Legislation and patient access schemes for medicinal cannabis
TGA presentation: Legislation and patient access schemes for medicinal cannabis
 
Ska
SkaSka
Ska
 
US, EU & Japan GMP Requirements: Practical ICH Area Differences & Healthcare ...
US, EU & Japan GMP Requirements: Practical ICH Area Differences & Healthcare ...US, EU & Japan GMP Requirements: Practical ICH Area Differences & Healthcare ...
US, EU & Japan GMP Requirements: Practical ICH Area Differences & Healthcare ...
 
New drug policy 1994
New drug policy 1994New drug policy 1994
New drug policy 1994
 
How to overcome the regulatory challenges due to brexit
How to overcome the regulatory challenges due to brexitHow to overcome the regulatory challenges due to brexit
How to overcome the regulatory challenges due to brexit
 
Centralize & decentralize regulatory framework of brazil and south africa
Centralize & decentralize regulatory framework of brazil and south africaCentralize & decentralize regulatory framework of brazil and south africa
Centralize & decentralize regulatory framework of brazil and south africa
 
Drug pricing policy india
Drug pricing policy indiaDrug pricing policy india
Drug pricing policy india
 
Ao 56 revised presentatio
Ao 56 revised presentatioAo 56 revised presentatio
Ao 56 revised presentatio
 

Similar to RK RA 2016

Pharma Regulatory Affairs in Argentina 2013
Pharma Regulatory Affairs in Argentina 2013Pharma Regulatory Affairs in Argentina 2013
Pharma Regulatory Affairs in Argentina 2013María Inés Guaia
 
Biocides - obligations and novelties
Biocides - obligations and noveltiesBiocides - obligations and novelties
Biocides - obligations and noveltiesUrskaPoje
 
Vigilare Biopharma Global Pharmacovigilance Regulatory Services Partner
Vigilare Biopharma Global Pharmacovigilance Regulatory Services PartnerVigilare Biopharma Global Pharmacovigilance Regulatory Services Partner
Vigilare Biopharma Global Pharmacovigilance Regulatory Services PartnerVigilare Biopharma
 
The Implications of Implementing the Directive on Falsified Medicines
The Implications of Implementing the Directive on Falsified MedicinesThe Implications of Implementing the Directive on Falsified Medicines
The Implications of Implementing the Directive on Falsified MedicinesEuropean Industrial Pharmacists Group
 
Why do you need accurate translations in regulatory affairs?
Why do you need accurate translations in regulatory affairs?Why do you need accurate translations in regulatory affairs?
Why do you need accurate translations in regulatory affairs?Agrooh Bioscience Translations
 
Pharm Sector In Laos
Pharm Sector In LaosPharm Sector In Laos
Pharm Sector In LaosIDS
 
Pharmacovigilance evmpd submission
Pharmacovigilance evmpd submissionPharmacovigilance evmpd submission
Pharmacovigilance evmpd submissioneCTDconsultancy
 
Rolf Panel Syhakhang
Rolf Panel SyhakhangRolf Panel Syhakhang
Rolf Panel SyhakhangIDS
 
Analysing the EU PVG regulations
Analysing the EU PVG regulationsAnalysing the EU PVG regulations
Analysing the EU PVG regulationsUntil ROI
 
Drug Regulations in India Dr Surinder Singh.pdf
Drug Regulations in India Dr Surinder Singh.pdfDrug Regulations in India Dr Surinder Singh.pdf
Drug Regulations in India Dr Surinder Singh.pdfwasimankhan
 
Vaccine Security meeting - Impact and opportunities for the new EU regulation...
Vaccine Security meeting - Impact and opportunities for the new EU regulation...Vaccine Security meeting - Impact and opportunities for the new EU regulation...
Vaccine Security meeting - Impact and opportunities for the new EU regulation...EuFMD
 
Functional foods law and regulations in Vietnam
Functional foods law and regulations in VietnamFunctional foods law and regulations in Vietnam
Functional foods law and regulations in VietnamVu Thi Thinh
 

Similar to RK RA 2016 (20)

Pharma Regulatory Affairs in Argentina 2013
Pharma Regulatory Affairs in Argentina 2013Pharma Regulatory Affairs in Argentina 2013
Pharma Regulatory Affairs in Argentina 2013
 
Session1: Patrick Deboyser, European Union
Session1: Patrick Deboyser, European UnionSession1: Patrick Deboyser, European Union
Session1: Patrick Deboyser, European Union
 
Biocides - obligations and novelties
Biocides - obligations and noveltiesBiocides - obligations and novelties
Biocides - obligations and novelties
 
Drug Administration GoAP - Shri BL Meena
Drug Administration GoAP - Shri BL MeenaDrug Administration GoAP - Shri BL Meena
Drug Administration GoAP - Shri BL Meena
 
Vigilare Biopharma Global Pharmacovigilance Regulatory Services Partner
Vigilare Biopharma Global Pharmacovigilance Regulatory Services PartnerVigilare Biopharma Global Pharmacovigilance Regulatory Services Partner
Vigilare Biopharma Global Pharmacovigilance Regulatory Services Partner
 
The Implications of Implementing the Directive on Falsified Medicines
The Implications of Implementing the Directive on Falsified MedicinesThe Implications of Implementing the Directive on Falsified Medicines
The Implications of Implementing the Directive on Falsified Medicines
 
Why do you need accurate translations in regulatory affairs?
Why do you need accurate translations in regulatory affairs?Why do you need accurate translations in regulatory affairs?
Why do you need accurate translations in regulatory affairs?
 
Pharm Sector In Laos
Pharm Sector In LaosPharm Sector In Laos
Pharm Sector In Laos
 
Pharmacovigilance evmpd submission
Pharmacovigilance evmpd submissionPharmacovigilance evmpd submission
Pharmacovigilance evmpd submission
 
Pharmaceutical Regulatory Affairs in Australia - by Youssef El-Nazer & Hamid ...
Pharmaceutical Regulatory Affairs in Australia - by Youssef El-Nazer & Hamid ...Pharmaceutical Regulatory Affairs in Australia - by Youssef El-Nazer & Hamid ...
Pharmaceutical Regulatory Affairs in Australia - by Youssef El-Nazer & Hamid ...
 
Rolf Panel Syhakhang
Rolf Panel SyhakhangRolf Panel Syhakhang
Rolf Panel Syhakhang
 
Analysing the EU PVG regulations
Analysing the EU PVG regulationsAnalysing the EU PVG regulations
Analysing the EU PVG regulations
 
Germany regulatory affairs
Germany regulatory affairsGermany regulatory affairs
Germany regulatory affairs
 
Drug Regulations in India Dr Surinder Singh.pdf
Drug Regulations in India Dr Surinder Singh.pdfDrug Regulations in India Dr Surinder Singh.pdf
Drug Regulations in India Dr Surinder Singh.pdf
 
Irum naila
Irum nailaIrum naila
Irum naila
 
Vaccine Security meeting - Impact and opportunities for the new EU regulation...
Vaccine Security meeting - Impact and opportunities for the new EU regulation...Vaccine Security meeting - Impact and opportunities for the new EU regulation...
Vaccine Security meeting - Impact and opportunities for the new EU regulation...
 
Functional foods law and regulations in Vietnam
Functional foods law and regulations in VietnamFunctional foods law and regulations in Vietnam
Functional foods law and regulations in Vietnam
 
Pharmaceutical Global Regulatory Affairs: Spain - by Aalmudena Camacho 2015
Pharmaceutical Global Regulatory Affairs: Spain - by Aalmudena Camacho 2015Pharmaceutical Global Regulatory Affairs: Spain - by Aalmudena Camacho 2015
Pharmaceutical Global Regulatory Affairs: Spain - by Aalmudena Camacho 2015
 
Josée hansen igz
Josée hansen   igzJosée hansen   igz
Josée hansen igz
 
Clinical Trials In Latin America
Clinical Trials In Latin America Clinical Trials In Latin America
Clinical Trials In Latin America
 

RK RA 2016

  • 1. Regulatory affairs service support Rayna Kostova Regulatory affairs and PV expert, MPharm Medicaldevices & medicovigilance Pricing and Reimbursement Rayna Kostova, Regulatory affairs and Pharmacovigilance services 1
  • 2. Registration of new medicinal products in EU countries: national MRP, DCP, CP preparation of documentation, negotiation with local Authorities and submission in Bulgaria (other EU countries) 2
  • 3. Variation procedures acc. to EU legislation preparation of documentation, negotiation with local Authorities and submission in Bulgaria (other EU countries) Product information changes, labelling and leaflet variations (acc. to QRD template requirements) 3
  • 4. Medical devices registration/notificati ons acc. to EU requirements preparation of documentation, negotiation with local Authorities and submission in Bulgaria (other EU countries) Product information: label, leaflet text translations, proof-reading for BG 4
  • 5. Biocidal products registration acc. to national and EU requirements preparation of documentation (technical dossier), negotiation with local Authorities and submission in Bulgaria (other EU countries) Product information: label, leaflet text translations, proof-reading for BG 5
  • 6. Food for special medical purposes, food supplement and cosmetic products registration/notifications acc. to EU requirements preparation of documentation, negotiation with local Authorities and submission in Bulgaria (other EU countries) Product information: label, leaflet text translations, proof-reading for BG 6
  • 7. Price registrations and reimbursement procedures preparation of documentation, negotiation with local Authorities and submission in Bulgaria (other EU countries) Market competitors prices research, long term pricing strategy with internal and external price referencing (17 Ref. countries for BG) Positive Drug list procedure for reimbursement by the National Health Insurance Fund and the hospital budget 7
  • 8. Pharmacovigilance and Medicovigilance services Literature screening for ADR ADR reporting to local Authorities in BG PSUR and RMP submission Service as a Qualified person for PV (QPPV) for the country Collecting and reporting AE for Medical devices 8
  • 9. Product complaint management Receive, process, report signals of complaints for drugs, medical devices, biocides, enteral nutrition products and cosmetics Plan and propose corrective and preventive actions (CAPA), submit FSN, perform recalls and report to Authorities Maintain complete database with complaint signals and CAPA performed acc. to internal and legal requirements 9
  • 10. Quality management system (QMS) Create and maintain a system of relevant SOP for RA, PV, GDP acc. to company requirements and local legislation Support company during preparation and conduction of internal/external ISO audits 10
  • 11. GOOD DISTRIBUTION PRACTICE (GDP) License as responsible pharmacist of local warehouse for medicinal products in Bulgaria Experience as warehouse manager acc. to local BG legislation requirements Compliance with EU Legislation changes support 11